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CHARACTERIZATION OF IGCR-1: A NOVEL MOLECULE WITH 
POTENTIAL ROLES IN LUNG CARCINOGENESIS  
CHRISTA MERCY LAM  
ABSTRACT 
 Non-small cell lung cancer (NSCLC) patients respond poorly to generic 
chemotherapeutics. Despite recent advancements in the treatment of NSCLC, the overall 
five-year survival rate of NSCLC remains low at 14.6%. We have identified 
Immunoglobulin-containing and Cysteine-rich Receptor (IGCR-1) as a putative cell 
surface protein, which is expressed in lung epithelial cells.  
The main objectives of this study were to evaluate expression of IGCR-1 in 
normal lung epithelium and lung carcinoma. Our analysis of publicly available ATCG 
data via bioGPS revealed that IGCR-1 is highly expressed in human lung. Moreover, our 
immunohistochemical studies further confirmed that IGCR-1 is expressed in bronchial 
epithelial cells. Additionally, IGCR-1 is expressed in endothelial cells of blood vessels 
and localized on the cell surface of human embryonic kidney cells. Its cell surface 
localization suggests that IGCR-1 could be a cellular adhesion molecule (CAM) with 
roles in the tumor microenvironment. Of note, the analysis of a panel of human lung 
carcinoma cell lines via western blot analysis demonstrated that IGCR-1 is expressed at 
variable levels in these cell lines. Given the heterogeneity of NSCLSs and the 
corresponding differential expression of IGCR-1 in different lung cancer cell lines, 
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Lung cancer is the most commonly diagnosed form of cancer (Street, 2018). 
However, despite advancement of diagnosis and treatment options, lung cancer remains 
the leading cause of cancer-related deaths in the United States and worldwide (Siegel, 
Miller, & Jemal, 2018). The American Cancer Society estimated 154,050 deaths from 
lung cancer in 2018, garnering a number of deaths greater than those caused by colon, 
pancreatic, and breast cancer combined (Siegel, Miller, & Jemal, 2018).  
Histologically, lung cancers are broadly categorized as non-small cell lung carcinomas 
(NSCLCs) or small-cell lung carcinomas (SCLCs) (Travis et al, 2011). These two groups 
are further divided into sub-types based on the anatomical origin of the cancer in the 
bronchial tree: (A) Squamous cell lung cancers, arising from the main bronchi, (B) 
Adenocarcinomas, arising from peripheral bronchi, (C) Large cell anaplastic carcinomas, 
arising from non glandular cells, and (D) NSCLC-not otherwise specified (NSCLC-NOS) 
(Travis et al, 2011). A general summary of lung carcinoma classification is summarized 
in Figure 1. NSCLCs represent 75-80% of lung carcinomas and epitomize the 




Figure 1: Flowchart of Lung Cancer Classification (Travis et al, 2011). 
 
Molecular Biology of Non-Small Cell Lung Carcinomas (NSCLCs)  
Non-small cell lung carcinoma patients manifest a wide range of histologic 
profiles that stem from each patient case’s dynamically different genetic mutation 
profiles and subsequent variety of phenotypic manifestations (Travis et al, 2011; 
Balgkouranidou et al, 2013; Pawlikowska et al, 2019). Prior to the understanding of 
NSCLCs’ remarkable genetic and molecular diversity, patients were historically treated 
with the same cytotoxic chemotherapeutic regimens such as carboplatin or cisplatin 
(Schiller et al., 2002). Regrettably, patients did not respond well, having poor tumor 
response rates between 20-30% and median survival duration of 8 months (Schiller et al., 
2002; Reck et al, 2016).  
In recent years, through the recognition of cell-signaling molecules like epidermal 
growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) 
as significant players in carcinogenesis, there has been an explosion of new lines of 
therapy (Dong et al, 2017). Recognition of EGFR as a targetable oncogenic mutation that 
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drives the malignancy of NSCLCs made precision medicine become more of a reality 
than a far-off dream (Mok et al, 2009). Targeting specific mutations in cancers as a viable 
treatment option was first explored and validated by team of researchers in 2011 who 
showed how targeting the translocation of Philadelphia chromosome chronic myeloid 
leukemia (CML) significantly improved tumor response rate (Druker et al, 2001). 
However, despite the initial promise relegated to new target therapeutics to improvie 
prognosis for NSCLC patients, severe limitations eventually followed (Visconti et al, 
2017). 
Erlotinib, a EGFR tyrosine kinase inhibitors (TKIs), was first tested for its 
potential as a standard of care chemotherapy for metastatic NSCLC patients based on the 
evidence that glycoprotein, EGFR, affects tumorigenesis through clear but complex roles 
in cell signaling (Shin et al, 1994; Shepherd et al, 2005; Steuer and Ramalingam, 2015). 
Erlotinib’s ability to prolong survival for NSCLC patients, previously treated with first-
line or second line chemotherapeutic, led to the development of many more of its kind, 
such as Gefitinib (Mitsudomi et al, 2010). Although intial groundbreaking studies 
boasted a longer progression-free survival (median 9.2 vs. 6.3 months) for NSCLC 
patients with EGFR mutations patients treated with an EGFR TKI (gefitinib) rather than 
standard chemotherapy, long-term studies showed lower overall survival (12.8 vs 19.8 
months) in the gefitinib group (Mitsudomi et al, 2010; Lee et al, 2017).     
 Because angiogenesis plays a major role in tumor progression, the design of 
adjuvant therapies to target VEGFRs, whose overexpression had been associated to poor 
prognosis for NSCLC patients, was also proposed (Han et al, 2001). VEGFR TKIs like 
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sorafenib and sunitinib target the activating tyrosine kinase domain of VEGFR and have 
been tested for patients with different cancers including hepatocellular carcinoma, 
gastrointestinal stromal tumor, renal cell carcinoma, and advanced NSCLCs (Llovet et al, 
2007; Escudier et al, 2007; Motzer et al, 2007; Gatzemeier et al, 2006; Socinski et al, 
2008). An overall analysis, however, indicates that NSCLC tumor response rates to 
VEGFR TKIs have remained stubbornly low (8-11%), with a mean progression-free 
survival no longer than 3.5 months (Subramanian, Morgensztern, and Govindan, 2010).  
Targeting oncogenic drivers in NSCLC like EGFR and VEGF have proven to be 
more effective than standard cytotoxic therapies. However, patients with metastatic 
NSCLC being treated with these lines of targeted therapies still have a low overall 5-year 
survival rate at 14.6% (Lin et al, 2016). Despite increased awareness of the toxic effects 
of smoking, advances in chemotherapeutics based on the identification of growth 
receptors, NSCLC persists in taking an alarming number of lives (Visconti et al, 2017). 
These facts could ultimately provoke one to wonder: are there other significant biological 
players in tumorigenesis that are not being rigorously considered, but should be?   
 
Tumor Microenvironment Giving Clues to Identify New Molecular Targets  
NSCLC tumor recurrence, often associated with developed resistance to targeted 
treatments like EGFR-TKIs, indicate how tumor cells are actively modifying and 
communicating with their microenvironment to sustain their survival at the face of 
adversity (Haber et al, 2005; Balkwill, Capasso, and Hagemann, 2012; Hui and Chen, 
2015).  Studying the tumor microenvironment (TME) consisting of a multitude of 
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characters including stromal cells, immune cells, fibroblasts, pericytes, adipocytes, blood 
vessels, extracellular matrix, and cell adhesion molecules would thus provide a different 
strategy in identifying new molecular targets (Quail and Joyce, 2013). Of particular 
interest for this study are the roles of cell adhesion molecules (CAMs) and molecules 
related to the endothelial barrier function. It has been previously shown in breast cancer 
that a specific CAM, vascular cell adhesion molecule-1 (VCAM-1), is a promising new 
therapeutic target (Sharma et al, 2017). Similarly in the context of pancreatic cancer, a 
tumor prone to developing resistance, CAMs have been actively studied to understand its 
role in the TME (Arcangeli, Crociani, and Bencini, 2014). Recently, the differential 
interplay between CAMs and immune cells (CD4, CD8 T-cells, B cells, and regulatory T-
cells) in NSCLC was described (Chae et al, 2018). This study showed how endothelial 
adhesion molecules and cellular barrier molecules could be potential biomarkers for 
immunotherapy due to their distinct roles in recruiting or decreasing immune cell 
infiltration.   
These studies have illustrated the convincing need to understand molecules of the 
TME in the context of breast and pancreatic cancer. Overall, however, the study of 
CAMs and the endothelial barrier is still in its early stages, especially in the context of 
the TME in NSCLCs. Consequently, there is also inadequate translation of research 
findings to clinical application, leaving patients suffering from recurrent disease with 





(A) Cell Adhesion Molecules 
Cell adhesion molecules (CAMs), including immunoglobulin superfamily 
(IgCAMs), integrins, and cadherins, have 2 main functions: (1) mediate cell-cell adhesion 
in the extracellular matrix, and (2) regulate activity of signaling molecules like receptor 
tyrosine kinases (RTKs) (Gibson, 2011). In normal development, CAMs are under tight 
regulation as they are responsible for vital cellular processes such as cell proliferation, 
migration, and differentiation (Gibson, 2011; Wong, Dye, and Coombe, 2012). Aberrant 
CAMs are exploited by tumor cells in order to avoid apoptosis, continue proliferation, 
invade surrounding tissue, and eventually metastasize (Wong, Dye, and Coombe, 2012; 
Hanahan and Weinberg, 2011). Despite their direct linkage to tumor metastasis, the full 
range of CAMs’ functions are still poorly understood. Hence, their potential as 
biomarkers or more effective treatment targets has not yet been fully leveraged.  
(1) N-cadherin and the Epithelial-Mesenchymal Transition 
 The hallmark of tumor metastasis is the epithelial-mesenchymal transition (EMT), 
in which normal epithelial cells lose their non-migratory nature, obtain mesenchymal 
phenotype, and the gain the ability to initiate immunosuppression, escape senescence, and 
effectively spread (Mrozik et al, 2018; Thiery et al, 2009; Gheldof and Berx, 2013). An 
example of a CAM playing a role in modulating tumor metastasis in the EMT is neural 
(N)-cadherin (Mrozik et al, 2018). During the EMT, epithelial (E)-cadherin loses 
expression and triggers the upregulated expression of N-cadherin. N-cadherin, unlike E-
cadherin, enhances the migratory and invasive behavior of tumor cells (Wheelock et al, 
2008). This phenomenon called the E-cadherin to N-cadherin switch currently serves as 
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an important biomarker for prostate cancer (Gravdal et al, 2007). Like N-cadherin, there 
may be many other CAMs whose upregulated or downregulated expression may imply its 
role in the metastasis of tumors. 
 
Novel Cell Adhesion Molecules Showing Evidence of Regulatory Roles in the TME  
Through screening the human genome for immunoglobulin (Ig)-containing 
proteins not yet identified, our lab found a family of novel molecules including: 
Immunoglobulin-Containing and Proline-Rich Receptor-1 (IGPR-1), Transmembrane and 
Immunoglobulin Domain-Containing 1 (TMIGD1), and Immunoglobulin-Containing and 
Cysteine-Rich receptor (IGCR-1). IGPR-1 is a 55kDa protein with an extracellular 
immunoglobulin domain, transmembrane domain, and proline-rich cytoplasmic domain, 
shown to play significant cell signaling roles in colon cancer (Rahimi et al, 2012). 
TMIGD1 is a highly conserved molecule in humans and other species, has been shown to 
play a regulatory in kidney cancers. (Arafa et al, 2015). IGCR-1, the third one of its 
family, has a unique cysteine-rich cytoplasmic domain that may contribute to its own 
characteristic regulatory roles in human cancers.  
(A) IGPR-1 Inhibits Colon Cancer Growth and Improves Chemotherapy 
Expressed exclusively in eukaryotes, IGPR-1 is the first novel cell adhesion 
receptor in its family to be identified and characterized (Rahimi et al, 2012). Although it 
is located in various human organs and tissues, IGPR-1 is found predominantly in 
epithelial and endothelial cells, functioning to regulate cellular morphology, focal 
adhesion, and angiogenesis (Rahimi et al, 2012). The identification of IGPR-1’s functions 
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are derived from its proline-rich cytoplasmic motifs found to be associated with Src 
homolog 3 (SH3) protein which interacts with Nck (SPIN90), a known molecule that 
regulates cellular adhesion by reorganizing actin cytoskeleton (Kaneko et al, 2008; 
Rahimi et al, 2012; Lim et al., 2001; Takenawa and Miki, 2001) 
IGPR-1 plays a role in modulating angiogenesis: an essential biological process 
that is starkly hijacked by tumor cells to advance their uncontrollable proliferation 
(Folkman, 1996; Holash et al, 1999, Leenders et al, 2002, Rahimi et al, 2012). Tumors 
become a garden of flourishing malfunctioned blood vessels n this process of pathogenic 
angiogenesis, causing the integrity of the endothelial barrier to be jeopardized (Baluk et 
al, 2005). Existing in cis-and trans-dimeric forms, IGPR-1 effectively regulates 
angiogenesis and the endothelial barrier adhesion function through trans-homophilic 
dimerization (Figure 2).  
 In colorectal cancer (CRC), one of the United States’ most common malignancies 
and the third most commonly diagnosed cancer, IGPR-1 is found to induce multicellular 
aggregation of colon tumor cells and increase their resistance to chemotherapeutics like 
doxorubicin (Siegal, 2017; Woolf et al, 2017). The effects of IGPR-1 decreasing the 
efficacy of well-known cytotoxic drugs such as doxorubicin make IGPR-1 a novel 
chemotherapeutic target (Woolf et al, 2017). These findings validate how CAMs play a 





Figure 2: Proposed Mechanism of IGPR-1’s Function. IGPR-1 regulates angiogenesis 
and the endothelial barrier function through trans-homophilic dimerization (Wang et al, 
2016).  
 
(B) TMIGDI: a Tumor Suppressor in Renal Cancer 
Acute kidney injury (AKI) and chronic kidney disease (CKD) are interrelated 
diseases with high mortality and morbidity rates, yet the underlying mechanisms of these 
diseases are still poorly understood (Chawla et al, 2014; Okusa, Chertow, and Portilla, 
2009). In 2015, TMIGD1, the second novel cell adhesion molecule in the IGPR family, 
was discovered to play significant regulatory and protective roles in renal tubular 
epithelial cells (Arafa et al, 2015). It regulates cell migration and cell morphology, as 
well as protects renal epithelial cells from damage caused by oxidative stress and nutrient 
deprivation (Arafa et al, 2015). With the identification of TMIGD1 as a novel cell 
adhesion molecule that protects renal epithelial cells from becoming susceptible to AKI 
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and CKD, the question of its potential role in renal cell carcinoma (RCC) naturally 
surfaced and sought to be answered. 
In human RCCs, TMIGD1 acts as a tumor suppressor (Meyer et al, 2017). This 
novel molecule showed evidence of regulating the induction of well-known cell cycle 
inhibitors: p21CIP1 and p27KIP1 (Meyer et al, 2017). Its expression is downregulated in 
human RCCs due to its direct relationship with downregulated transcription factor 
regulator CCAAT/enhancer-binding proteinβ (C/EBPβ) observed in renal cancers (Meyer 
et al, 2017; Nerlov, 2007). Interestingly enough, over-expressed TMIGD1 in renal tumor 
cells showed significant tumor growth arrest and decreased tumor metastatic activities 
such as morphogenic branching and cell migration. The discovery of TMIGD1 and the 
characterizing studies that elucidated its function affords researchers and clinicians a new 
angle of approach to not only better understand the pathobiology of RCC, but also to 
design more effective therapies for renal cancer patients.  
 (C) Immunoglobulin-Containing Cysteine Rich (IGCR-1) is expressed in Lung 
Epithelial Cells: A Potential Role for IGCR1 in Lung Carcinoma  
 In a similar manner, IGCR-1 is now being characterized to understand its 
regulatory role in the context of NSCLCs tumorigenesis. Immunoglobulin-Containing 
and Cysteine-Rich receptor (IGCR-1) was originally identified as one of 386 putative 
uncharacterized cell-surface proteins based on a full analysis of the human genome along 
with IGPR-1, TMIGDI, and MINAR1 (Rahimi et al, 2012; Arafa et al, 2015; Ho et al, 
2018). Composed of 407 amino acids, IGCR-1 is predicted to have a molecular weight of 
45kDa (unpublished data). In silico analysis suggested that IGCR-1 is a cell surface 
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molecule with three characteristic domains: 1) two immunoglobulin domains, 2) a 
transmembrane domain, and 3) a cysteine-rich cytoplasmic domain. IGCR-1 was 
determined to be highly expressed in lung epithelial cells and predicted to have roles in 
regulating lung carcinoma.  
 
Figure 3: Proposed Structure of IGCR-1. The structure of putative molecule, IGCR-1, 
has three characteristic domains: (1) two immunoglobulin domains, (2) one 
transmembrane domain, and (3) a cysteine-rich cytoplasmic domain (unpublished data).  
 
The overall goal of this project was to examine expression of IGCR-1 in lung 
carcinoma and specifically test the hypothesis that IGCR-1 is differentially expressed in 
human lung carcinoma.  
The specific aims of this project are as follows: 
I. Determine the expression of IGCR-1 in normal lung tissue, identify the cell types that 
are positive for IGCR-1, and test the hypothesis of IGCR-1 as a cell surface molecule.  
II. Determine expression of IGCR-1 in human lung cancer cell lines.  
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III. Determine expression status of IGCR-1 in different staged human lung carcinomas 
and identify the tumor and/or stromal cell types in the tumor microenvironment that are 





Antibodies and General Reagents  
  Rabbit polyclonal anti-IGCR-1 antibody was developed as previously described 
(Rahimi et al, 2012). Anti-IGCR-1 antibody was used in 1:2000 dilutions for western blot 
analysis and immunofluorescence analysis. 1:5000 dilutions of anti-IGCR-1 antibody was 
used for immunohistochemical analysis of the panel of human lung cancer samples 
purchased from US Biomax, but 1:2000 dilutions were used for all other 
immunohistochemistry experiments. Mouse monoclonal anti-GAPDH antibody was 
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and used at 1:1000 
dilutions. Immunohistochemistry staining kit including peroxidase and protein blocking 
reagents, biotinylated secondary antibody, streptavidin-Horseradish peroxidase (HRP), 
and 3,3'-diaminobenzidine (DAB) substrate was purchased from Abcam. Hematoxylin 
was purchased from Thermo Scientific™. 
 
Cell Culture 
  Human embryonic kidney cell line (HEK-293), HEK-IGCR-1, and 293-GPG cells 
were grown in Dulbecco’s Modified Eagle’s Media (DMEM) supplemented with 10% 
fetal bovine serum (FBS). Lung cancer cell lines including A549, H1299, H3030, and 
PC-9 were maintained in Roswell Park Memorial Institute Medium (RPMI). All cell lines 
were kept at 37˚C and 5% CO2 conditions by Thermo Scientific humidified CO2 
incubators.  
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Retroviral Virus Production 
pMSV.puro vector containing IGCR-1 sequence and cMyc tag was transfected 
into 70-80% confluent human 293-derived retroviral packaging cell line (293-GPG) 
grown in GPG growth media (DMEM, 10% FBS, 2mM L-glutamine, and 50 units/mL 
penicillin and streptomycin). After 24-hour incubation, virus-producing media replaced 
GPG growth media. Viral supernatant was collected over 3 days, at 72, 96, and 120 hours 
(Rahimi et al, 2000). HEK-293 cells expressing IGCR-1 were produced using this 
retroviral system. DMEM containing 10% FBS and 1µg/mL puromycin was used to 
select for successfully transduced cells.  
 
Immunohistochemical Analysis 
Wild-type mice were subjected to organ extraction. Isolated organs were 
subjected to standard procedures of formalin fixation and paraffin embedding (FFPE). 
Tissue sections were prepared with Microtome (Model HM 325) and Boekel Lighted 
Tissue Flotation Bath III (Model 145702). After baking overnight at 60˚C, tissue slides 
underwent hydration steps with Pro-Par clearant. Samples were placed in citrate buffer at 
pH 6.0 and heat-induced epitope retrieval steps were achieved through the BioCare 
Medical Decloaking chamber. Primary antibodies were diluted into serum-free protein 
block overnight at 4˚C to 1:2000 or 1:5000 dilutions of anti-IGCR-1 rabbit polyclonal 
antibody. Antibody detection was preformed using 30-minute incubation with anti-rabbit-
HRP. Washes were performed with 0.05% tris-buffered saline polysorbate (TBS Tween). 
Slides were subjected to 40 seconds of DAB chromagen and 40 seconds in Hematoxylin. 
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After dehydration, slides were mounted with VectaMount® Permanent Mounting 
Medium. 
Human breast cancer and leiomyosarcoma tissue samples were provided by 
Boston Medical Center with IRB approval. Lung carcinoma progression tissue 
microarray (LC1005a) containing 15 cases of squamous cell carcinoma, 15 
adenocarcinoma, 8 large cell carcinoma, 8 lymph node metastasis carcinoma, 46 matched 
or unmatched adjacent normal tissue, plus 8 normal lung tissue was purchased from US 
Biomax, Inc.  
 
Western Blot Analysis 
  Cell lysates were made when cells were 70-90% confluent. Two washes with H/S 
buffer (25mM Hepes (pH 7.4)/150mM NaCl) and aspiration were performed to remove 
excess media and cellular debris. Lysis buffer (10mM Tris-HCl, 10% Glycerol, 5 mM 
EDTA (pH 7.4), 50 mM NaCl, 50 mM NaF, 1% Triton X-100, 1 mM 
phenylmethylsulfonyl fluoride, 20 mg/ml aprotinin, 15µL phosphatase inhibitor, 10µL 
NaVIO4) was used. Samples were subjected to centrifugation at 15,000 rpm for 15 
minutes at 4˚C. After collection of supernatant, 5X sample buffer (3.8% Tris-base, 50% 
glycerol, 5% sodium dodecyl sulphate (SDS), 5% β-mercaptoethanol, 0.0025% 
bromophenol blue) was added to samples and subsequently vortexed and heated at 95-
100˚C for 3-5 minutes.  
 12% SDS-polyacrylimide resolving gel (SDS-PAGE) and 2X stacking gel were 
made. Samples were subjected to 35mA for 30-60 minutes and to 45mA for 4-5 hours 
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until significant separation between 43kDa and 55kDa bands as indicated by EZ-RunTM 
prestained rec-protein ladder purchased from Fisher BioReagentsTM. Proteins were 
transfered onto polyvinlidene difluoride (PVDF) membranes. Membranes were incubated 
in blotto (2% non-fat dry milk and 0.05% Tween-20 in Western Rinse) for 1 hour at room 
temperature or overnight at 4˚C. 1:10,000 dilutions of secondary rabbit or mouse were 
used. Membranes were developed using enhanced chemiluminescence (ECL).  
 
Immunofluorescence Microscopy 
  An estimated 7.5-8.5 x 104 cells were seeded in 6cm plates. Ethanol and 15 
minutes of ultraviolet germicidal irradiation were utilized for sterilization. HEK-293 cells 
were transfected with E-cadherin GFP and grown to become 80-90% confluent. Cells 
were fixed in 4% paraformaldehyde for 15 minutes and subjected to permeabilization 
with 0.1% sodium citrate and 0.1% Triton X-100. Samples were incubated for one-hour 
with anti-IGCR-1 antibody (1:2000) and subsequently incubated for one-hour with anti-
rabbit secondary antibody (1:750). Three washes with non-sterile phosphate buffered 
saline at five minutes each were performed before and after primary and secondary 








IGCR-1 is highly expressed in specific cell types of normal lung tissue  
We began our study with a preliminary screening of a panel of cell types from 
major organs to predict IGCR-1 expression levels by its transcript frequency in different 
cell types using publicly available ATCG data via bioGPS. From this analysis, we found 
that the IGCR-1 transcript was most prevalent in bronchial and airway epithelial cells, 
suggesting higher expression levels in these cell types (Figure 4). Albeit at lower levels, 
IGCR-1 transcript was also detected in a variety of other cell types including ones of the 
nasopharyngeal epithelium, medial temporal gyrus, and plasma (Figure 4).  
  
Figure 4: IGCR-1’s predicted expression across a panel of cell types using bioGPS 
database. Preliminary screening of IGCR-1 transcript levels suggested that IGCR-1 is 




To validate this finding, we continued our study with immunohistochemistry 
(IHC) staining of a mouse tissue array to determine whether IGCR-1 would be more 
highly expressed in lung epithelial cells than other cell types and tissues. Indeed, lung 
tissues showed the strongest indication of IGCR-1 expression (Figure 5e). Additionally, 
compared to the control, cuboidal shaped ciliated bronchiole epithelial cells indicated the 
highest intensity staining of IGCR-1, specifically in certain apical regions (Figure 5a). 
These findings were consistent in human lung tissue (Figure 5b). Smooth muscle cells, 
endothelial cells, and apical regions of enterocytes also expressed IGCR-1 (Figure 5a, c-
d), but at lower levels compared to lung bronchial epithelial cells (Figure 5e). Cell types 




Figure 5: IGCR-1’s expression across a panel of cell types and specific cell-types 
expressing high levels of IGCR-1 from immunohistochemical (IHC) analyses. (A) 
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IGCR-1 is expressed in mouse ciliated bronchial epithelial cell types with higher intensity 
in select apical regions and at lower intensity in smooth muscle cells. (B) Similar IGCR-1 
expression profile in human lung tissue. (C-D) IGCR-1 is expressed in endothelial cells 
and enterocytes with less staining intensity. (E) Summarized indications of IHC analyses 
showing relatively insignificant level of IGCR-1 expression observed in eye, skin, and 
brain tissues. Slides were visualized in light microscope at 20X.  
 
IGCR-1 is a cell-surface molecule 
To further characterize this novel molecule, we wanted to investigate its cellular 
localization. From its putative amino acid sequence, IGCR-1 was predicted to be a cell 
surface receptor with two immunoglobulin domains, a transmembrane domain, and a 
cysteine-rich cytoplasmic domain (Figure 3). Our initial results using 
immunofluorescence indicate that IGCR-1 is localized on the cell surface of human 
embryonic kidney 293 cells (HEK-293), having insignificant overlapping expression with 
the control staining cellular nuclei (Figure 6). Western blot analysis was done with 
GAPDH loading control to validate IGCR-1 expression in HEK-293 cells (Figure 6).  
	
                            
Figure 6: Preliminary results testing hypothesis of IGCR-1 as a cell surface molecule 
using immunofluorescence microscopy. HEK-293 cells show IGCR-1 (Texas red) 
localized on the cellular surface. Control with DAPI (blue) stained for nuclei. Slides were 
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visualized under immunofluorescence microscope at 40X. Expression of IGCR-1 in 
HEK-293 cells is verified using western blot analysis and GAPDH as loading control. 
 
Differential expression of IGCR-1 in cancer cell lines 
To evaluate expression of IGCR-1 in human lung cancer cell lines, we used a 
panel of cancer cell lines and found that IGCR-1 was variably expressed in different 
human cancers (Figure 7). Among nine cancer cell lines, four cell lines consisting of 
breast carcinoma (BT-20), colorectal adenocarcinoma (HT-29), amelanotic skin 
melanoma (A-375), and skin melanoma (UACC-62) showed the greatest protein levels of 
IGCR-1 (Figure 7). The remaining cancer cell lines did not have significant levels of 
IGCR-1 compared with GAPDH loading control (Figure 7). Interestingly, differential 
expression of IGCR-1 was also observed within cancer cell lines of the same organs. For 
example, although colorectal adenocarcinoma (HT-29) showed positive expression of 
IGCR-1, other cancer cell lines of the kidney such as kidney carcinoma (A-498), clear 
cell renal cell carcinoma (CAK1-1), colorectal carcinoma (HCT 116), and renal cell 
adenocarcinoma (786-0) did not indicate having significant protein levels of IGCR-1 
(Figure 7). In the same way, for skin cancers, malignant skin melanoma (SK-MEL-2) did 
not have indications for positive IGCR-1 expression despite positivity observed in 




Figure 7: Western blot analyses to determine specific cancer cell lines expressing 
IGCR-1. Breast carcinoma (BT-20), colorectal carcinoma (HCT 116), amelanotic skin 
melanoma (A-375), and skin melanoma (UACC-62) cell lines indicated positive IGCR-1 
protein levels compared to GAPDH loading control. 
 
IGCR-1 is downregulated in breast cancer and leiomyosarcoma 
To elucidate its role in cancer biology, we continued our analysis by doing IHC 
comparison studies to observe whether or not IGCR-1 expression levels differed in tumor 
cell types compared with normal cell types. We performed IHC analysis on five different 
breast cancer patient cases. Normal ductal breast cell types stained much more intensely 
than tumor ductal cell types (Figure 8a, Case 1). Areas of metastasis showed even lower 
expression levels of IGCR-1, consistent with evidence of IGCR-1 downregulation in 
tumorigenesis (Figure 8a, Case 2). To test whether this trend is maintained in other 
cancer types, nine smooth muscle tumor (leiomyosarcoma) patient cases also underwent 
IHC staining to probe for IGCR-1. Again, when compared with normal smooth muscle 
cells of large arteries, smooth muscle cells of leiomyosarcomas showed evidence of 




Figure 8: IHC comparison analyses of human breast cancers and leiomyosarcoma. 
(A) Case 1: Normal breast ductal cells stained more intensely for IGCR-1 than tumor 
ductal cells. Case 2: The arrow points to area of normal ductal cells in metastatic breast 
cancer. Metastatic areas localized on left side of sample. (B) IGCR-1 positive normal 
smooth muscle cells of large arteries compared with IGCR-1 downregulation in smooth 
muscle cells of leiomyosarcoma. Slides were visualized in light microscopy at 10X.  
 
IGCR-1 expression is maintained in endothelial cells of breast cancer and 
leiomyosarcoma 
Because previously studied molecule in IGCR-1’s family, IGPR-1, was shown to 
have modulating effects on angiogenesis, we wanted to explore the level of IGCR-1 
expression in endothelial cells of the tumor microenvironment compared with endothelial 
cells in normal tissues. As shown before, IGCR-1 is expressed in endothelial cells of 
normal lung tissues (Figure 5C). Western blot analysis of an umbilical vascular 
endothelium cell line (HUVECT-TERT) also illustrated positive IGCR-1 protein levels in 
normal endothelial cells (Figure 9C). However, contrary to the phenomenon of 
downregulation observed in ductal breast and smooth muscle tumor cells, IGCR-1 
showed no evidence of downregulation in endothelial cells of the breast and smooth 
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muscle tumor microenvironment when compared to those of normal blood vessels 
(Figure 9A-B). Countless microvessels in leiyosarcomas and breast cancer samples 
stained positively for IGCR-1 (Figure 9A-B). In addition, endothelial cells of the large 
arteries in leiomyosarcomas stained positively for IGCR-1 (Figure 9A).  
 
 
Figure 9. Positive IGCR-1 expression in endothelial cells of the tumor 
microenvironment and in normal endothelial cell line (HUVEC-TERT). (A) Vast 
numbers of microvessels and large arteries stained positively for IGCR-1 in 
leiomyosarcomas (B) Microvessels within metastatic breast tumor environment also 
indicated positive levels of IGCR-1. (C) IGCR-1 is present in normal umbilical vascular 
endothelium cell line (HUVEC-TERT). Slides were visualized in light microscopy at 
10X.  
 
IGCR-1 expression has an inverse relationship with non-small cell lung cancer 
staging  
Finally, we come to the core of our investigation to determine IGCR-1’s potential 
role as a novel molecule in lung carcinogenesis. In order to elucidate its function in lung 
carcinogenesis, we wanted to determine the correlation between IGCR-1 expression and 
the progression of NSCLCs. To do this, we carried out IHC analysis of a lung carcinoma 
progression tissue microarray consisting of cases from all three subtypes of NSCLCs: 
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adenocarcinomas, squamous cell carcinomas, and large cell anaplastic carcinomas. Our 
results showed a gradual decrease of IGCR-1 expression with each progressive stage of 
carcinoma (Figures 10-12). Non-small cell lung cancer cell line, H3030, also exhibited 
low expression of IGCR-1 when compared with positive control (HEK-IGCR1) in 
western blot analysis (Figure 10a). Additionally, endothelial cells of microvessels of lung 
squamous carcinomas exhibited positive expression of IGCR-1 in a similar fashion as 
visualized in breast cancer and leiomyosarcoma tissues (Figure 11C).  
 
A) IGCR-1 is downregulated in lung adenocarcinomas  
 Adenocarcinomas represent the majority of NSCLCs at 38.5% of all lung cancers 
(Howlader et al, 2010). Hence, we wanted to begin with the results for IGCR-1 
expression levels in this specific category of NSCLCs. Results showed significant 
downregulation of IGCR-1 with each progressive stages (Figure 10b-d). Western blot 
analysis showed that, compared with the positive IGCR-1 control (HEK-IGCR1), lung 
adenocarcinoma cell lines (A549 and PC-9) showed lower levels of IGCR-1 (Figure 10a). 
This is consistent with IHC findings of IGCR-1 being downregulated in breast and 





Figure 10. Downregulation of IGCR-1 in later staged lung adenocarcinomas. (A) 
Cell lysates from human lung adenocarcinoma (A549), large-cell lung carcinoma 
(H1299), non-small cell lung carcinoma (H3030), and lung adenocarcinoma (PC-9) were 
subjected to western blot analysis with anti-IGCR-1 and anti-GAPDH antibody as 
loading control. HEK-IGCR-1 was used for positive control and had a higher molecular 
weight around 46kDa due to cMyc-tag. (B) IHC analysis showed strong IGCR-1 staining 
in stage I adenocarcinoma. (C) Stage II indicated decreased staining. (D) No significant 
staining visualized in stage IIIB adenocarcinoma. Slides were visualized in light 
microscopy at 10X.  
 
B) IGCR-1 is progressively downregulated in lung squamous cell carcinomas 
(SCCs)  
In a similar way, IGCR-1 is progressively downregulated with later staged lung 
squamous cell carcinomas (Figure 11).  Relative to stage 1 and 2 lung adenocarcinomas 
(Figure 10b-c), stage 1 and 2B SCCs in IHC analysis expressed lower levels of IGCR-1 
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(Figure 11a-b). Interestingly, IGCR-1 maintained expression in numerous microvessels 
of stage IIIA sample SCC (Figure 11c). This is consistent with a previous observation of 
positive IGCR-1 expression in endothelial cells of breast cancer and leiomyosarcomas 
(Figure 9a-b).  
 
Figure 11. Downregulation of IGCR-1 in squamous cell carcinoma (SCC). (A) An 
example of a stage I SCC section showing moderate staining of IGCR-1 (B) Insignificant 
levels of IGCR-1 in a stage IIB SCC sample (C) Low expression of IGCR-1 in a stage 
IIIA SCC sample, but maintained expression of IGCR-1 in endothelial cells of 
microvessels. Slides were visualized in light microscopy at 10X.  
 
C) Higher expression of IGCR-1 in early staged large cell anaplastic tumors 
compared with other NSCLCs and similar downregulation in later staged tumors 
 Finally, we end with the least common type of lung cancers, large cell lung 
carcinomas, which make up 2.9% of all lung cancers (Howlader et al, 2010). For this 
category of NSCLCs, greater levels of IGCR-1 were observed in early stages of the 
cancer at stage IB and II (Figure 12a-b) compared with early staged lung 
adenocarcinomas and SCCs (Figures 10-11). More specifically, stage II large cell 
anaplastic tumor still expressed noticeable levels of IGCR-1 whereas stage II lung 
adenocarcinomas and stage IIB SCCs did not (Figure 12b, 10c, and 11b). This may 
correlate with western blot analysis showing greatest relative protein levels of IGCR-1 in 
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large-cell lung carcinoma cell line (H1299) compared with other NSCLC cell lines 
(Figure 10a).  
 
Figure 12. IHC analysis showing higher levels of IGCR-1 in large cell anaplastic 
carcinoma compared with other NSCLCs and downregulation of IGCR-1 with 
progressive staging. (A) High level of IGCR-1 expression in stage IB large cell 
anaplastic carcinoma sample (B) Sample of stage II carcinoma had decreased IGCR-1 
levels but still noticeable amounts (C) Low expression of IGCR-1. Intense stains in stage 
IIIA sample do not bear resemblance to IGCR-1 pattern of staining and are most likely 








Our study demonstrates that IGCR-1 is expressed in lung bronchiole epithelial 
cells. Its expression, however, progressively trends towards downregulation in non-small 
cell carcinomas (NSCLCs). 
Analysis of bioGPS dataset for IGCR-1 transcript combined with our IHC 
analysis of mouse and human tissues revealed that IGCR-1 is highly expressed in 
bronchiole epithelial cells. Moreover, our initial immunoflourescent results indicate that 
IGCR-1 may be a cell-surface molecule. Its cell surface localization suggests that IGCR-
1 could be a cellular adhesion molecule (CAM) with roles in the tumor 
microenvironment. 
Bronchial epithelial cells consist of ciliated and non-ciliated cells that are 
specifically involved in defending the lungs from toxic substances (Knight and Holgate, 
2003). Club cells (Clara cells), the non-ciliated cells of the bronchiole epithelium, aid in 
forming a protective barrier for the bronchiolar epithelium, metabolizes xenobiotic 
substances inhaled from the environment, and generates new cells to replenish the 
epithelium (Komáromy and Tigyi, 1988; Knight and Holgate, 2003). There is a high level 
of communication between cells of the bronchiole epithelium and cell types outside the 
epithelium such as stromal cells, fibroblasts, smooth muscle cells, mononuclear cells, 
lymphocytes, endothelial cells, and myofibroblasts (Thompson et al, 1995; Holgate, 
2000). Taken together, the highly specific expression of IGCR-1 in the bronchiolar 
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epithelium and its cell-surface properties point to its potential roles in mediating 
communication between a diverse number of cell types.  
 To develop this thought further, aberrant communication, especially between cells 
with progenitor functions such as club cells, may then drive carcinogenesis (Crystal et al, 
2008). Thus, we propose that insufficient expression of IGCR-1 may cause defective 
communication between cell types and lead to carcinogenesis. Our findings from IHC 
and western blot analyses revealed that IGCR-1 expression is significantly reduced or 
non-detectable in breast cancer, leiomyosarcoma, and three types of later staged 
NSCLCs. These observations are consistent with the hypothesis that IGCR-1 is an 
important mediator of cellular communication and subsequent downregulation could 
cause tumorigenesis. Tumor cells showing downregulation of IGCR-1 compared with 
normal tissues may suggest that 1) tumor cells selectively mutate to decrease expression 
of IGCR-1 in order to maintain its survival and eventually achieve metastasis, or 2) 
genetic or structural mutations that decrease functional levels of IGCR-1 may catalyze 
tumorigenesis. 
 Interestingly, our IHC analysis yielded a seemingly paradoxical phenomenon of 
IGCR-1 expression in the blood vessels surrounding tumors. Although IGCR-1 is 
consistently downregulated in tumor cells of breast, smooth muscle, and lung cancers, its 
expression was maintained in the blood vessels that were associated with these tumor 
samples. This unique expression profile of IGCR-1 in tumor-associated vasculature may 
suggest that it has a different role in tumor-associated blood vessels than in the tumor 
cells themselves.   
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 Understanding the tumor microenvironment by exploring the expression and 
associated function of novel molecules can give us new perspectives and insights on the 
nature of cancers. Specifically, in our study of IGCR-1, the novel molecule was found to 
be expressed in lung bronchiole epithelial cells and subsequently regulated in diverse 
ways depending on cell types in the tumor microenvironment. This complex 
manifestation of IGCR-1’s expression complements the known complexity and 
heterogeneity in NSCLCs.  
 The design and development of effective treatment plans for cancer patients, 
specifically for NSCLC patients, will not be a simple feat. Carcinogenesis involves a host 
of mutations and aberrant functioning molecular players. Developing treatment plans that 
simply target one of the many players such as EGFR or VEGF TKIs have proven 
insufficient, as treated tumors have shown evidence of recurrence due to developed 
resistance to such therapies. Consequently, there may be a need for adjunct therapies to 
complement existing therapeutics that target novel molecules in the tumor 
microenvironment. IGCR-1 is one such molecule that offers potential as a biomarker or 
target for the development of adjunct therapies to help treat patients with NSCLCs.  
Although preliminary in nature, our studies have provided a foundation upon 
which we can springboard the design of succeeding studies and directed biochemical 
assays to understand IGCR-1’s function in the context of cancer biology. Further 
investigation of molecules such as IGCR-1 will prove fruitful, as knowledge of novel and 
unique molecules in the tumomicroenvironment will paint another dimension to our still 
limited understanding of lung carcinogenesis. This, in turn, could propel innovative 
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engineering of novel therapies to complement or replace conventional therapeutics that 
are still largely ineffective at improving the five-year survival rate for NSCLC patients. 
Ultimately, IGCR-1 may offer direction in the continued search for more effective 
treatments or diagnostic tools for NSCLC patients, making the effort to fully characterize 
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